Drug
Kyv 101
Kyv 101: highest development phase Phase 2, developed by Kyverna Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Kyverna Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| KYV-101 NCT06384976 | Phase 2 | Multiple Sclerosis, Primary Progressive |
| KYV-101 NCT06400303 | Phase 1/2 | Systemic Sclerosis |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 | Phase 1/2 | ANCA-IgG-positive ANCA Associated Vasculitis |
| KYV-101 NCT06152172 | Phase 1 | Idiopathic Inflammatory Myopathies |
Latest
No recent events.
Follow Kyv 101 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.